Pfizer and CytomX collaborate in $610M Probody deal

Pfizer and CytomX have announced that they have entered into a collaboration to develop and commercialize multiple ‘Probody-Drug Conjugates' (PDCs) for use in oncology.  The antibody-masking technology blocks the Probodies' binding ability in healthy tissue, and relies upon disease-associated dysregulated protease activity to ‘unmask' the binding sites only in diseased tissue. The fully recombinant masked antibodies therefore remain inert in …